Philips is set to invest over $150m in US manufacturing and research and development (R&D) to enhance its AI-powered health technology offerings.
The initiative builds on Philips’ existing $900m annual research and development (R&D) investment in the US to bolster local manufacturing capabilities.
The investment includes the expansion of the company’s manufacturing facility in Reedsville, Pennsylvania.
The Reedsville facility produces AI-enabled ultrasound systems for US hospitals.
The expansion will add 24,000ft2 of manufacturing space and 40,000ft2 of warehouse space, creating 120 skilled manufacturing jobs.
The facility, which currently produces transducers, will also customise ultrasound software for specific procedures in cardiovascular, general, and maternal care.
In addition, Philips is expanding its Image Guided Therapy facility in Plymouth, Minnesota, with a new medtech training centre, expected to generate over 150 jobs.
Philips North America chief region leader Jeff DiLullo said: “The proposed planned expansion of our manufacturing facilities is a demonstration of our deep commitment to the US region.
“Each year, Philips spends $900m in R&D in the US to drive innovation and deliver cutting-edge technology that empowers healthcare professionals to diagnose, treat and monitor patients more effectively.
“Increasing our manufacturing and R&D capabilities will create jobs and accelerate our ability to deliver better care for more people with innovative AI-enabled solutions.”
Last month, Philips secured 510(k) approval from the US Food and Drug Administration (FDA) for its SmartSpeed Precise dual AI software.
The software, designed to optimise MRI scans, promises up to three times faster scanning and 80% sharper images, enhancing AI-powered MRI technology.
SmartSpeed Precise can be used across Philips’ entire range of 1.5T and 3.0T MRI systems, including existing installations.
